USPTO Boosts Fast-Track Patents to 20,000 for Inventors
Published Date: 7/8/2025
Rule
Summary
Good news for inventors! The USPTO is raising the yearly cap on fast-tracking patent reviews from 15,000 to 20,000 requests. This means more people can speed up their patent applications starting October 1, 2024, helping ideas get protected quicker without extra fees.
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
More Fast-Track Patent Slots
If you apply for a U.S. patent, the USPTO will accept up to 20,000 prioritized examination requests in a fiscal year (October 1 to September 30) instead of 15,000. This change starts October 1, 2024 and allows up to 5,000 more applicants each year to speed up their patent reviews without extra fees.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-17524, Agency Information Collection Activities; Submission to the Office of Management and Budget for Review and Approval; Comment Request; Patent Trial and Appeal Board (PTAB) Appeals
The United States Patent and Trademark Office (hereafter "USPTO" or "Agency") will submit the following information collection request to the Office of Management and Budget (OMB) for review and clearance in accordance with the Paperwork Reduction Act of 1995, on or after the date of publication of this notice. The USPTO invites comments on the information collection renewal of 0651-0063, which helps the USPTO assess the impact of its information collection requirements and minimize the reporting burden to the public. Public comments were previously requested via the Federal Register on April 20, 2026, during a 60-day comment period (91 FR 20986). This notice allows for an additional 30 days for public comments.
2026-17525, Agency Information Collection Activities; Submission to the Office of Management and Budget for Review and Approval; Comment Request; Substantive Submissions Made During the Prosecution of the Trademark Application
The United States Patent and Trademark Office (hereafter "USPTO" or "Agency"), as required by the Paperwork Reduction Act of 1995, invites comments on the extension and revision of an existing information collection: 0651-0054 (Substantive Submissions Made During the Prosecution of the Trademark Application). The purpose of this notice is to allow 60 days for public comments preceding submission of the information collection to the Office of Management and Budget (OMB).
2026-16744, Request for Comments on Community Outreach Office Locations in the Southwest States
The USPTO wants your ideas on where to open new community outreach offices in the Southwest states like Arizona and Texas. These offices will help inventors, small businesses, and students get better support with patents. Share your thoughts by September 16, 2026, so the USPTO can pick the best spots and keep innovation booming without extra costs to you!
2026-16315, Administrative Updates to the General Requirements Bulletin for Admission to the Examination for Registration To Practice in Patent Cases Before the United States Patent and Trademark Office
Starting August 11, 2026, the USPTO is upgrading Biomedical Science degrees from Category B to Category A for patent bar eligibility. This means more people with this degree can now take the patent exam and become patent practitioners. No extra fees or delays—just a smoother path for those with the right science background to join the patent world!
2026-14939, Grant of Interim Extension of the Term of U.S. Patent No. 8,877,798; Centanafadine Hydrochloride
Otsuka America Pharmaceutical got a one-year extra patent life for their drug centanafadine hydrochloride because the FDA review is still going on. This means their patent, which was set to expire on July 25, 2026, now lasts until July 25, 2027. This extension helps Otsuka keep exclusive rights to their drug a bit longer while waiting for final FDA approval.
2026-14941, Grant of Interim Extension of the Term of U.S. Patent No. 8,461,196; Centanafadine Hydrochloride
Otsuka America Pharmaceutical got a one-year extra patent life for their drug centanafadine hydrochloride because the FDA review is still going on. This means they keep exclusive rights to the drug until July 25, 2027, giving them more time to sell it without competition. This extension helps the company protect their investment while the drug gets final approval.
Previous / Next Documents
Previous: 2025-12626, National Emission Standards for Hazardous Air Pollutants for Coke Ovens: Pushing, Quenching, and Battery Stacks, and Coke Oven Batteries; Residual Risk and Technology Review, and Periodic Technology Review
The EPA is giving coke oven operators more time to meet new pollution rules by pushing deadlines from 2025 and 2026 to 2027. This helps companies keep the air cleaner without rushing to meet tough standards. If you run or work with coke ovens, watch for these updated deadlines and get ready to comply by mid-2027.
Next: 2025-12646, Safety Zones; Fireworks Displays in the Fifth Coast Guard District, Brick Township, NJ
The Coast Guard is setting up safety zones around Brick Township, NJ, for four fireworks shows in July to keep everyone safe on the water. Boat operators in these zones must follow Coast Guard instructions during the events. This means some water areas will be off-limits temporarily, but no fees or costs are involved.